Relmada Therapeutics (RLMD) Short-Term Debt issuances (2019 - 2020)
Relmada Therapeutics (RLMD) reported Short-Term Debt issuances of -$110247.0 for Q1 2020, down 28.24% year-over-year from -$153633.8 in Q2 2019, and up 50.57% on a QoQ basis from -$223017.0 in Q3 2019.
Relmada Therapeutics (RLMD) has 2 years of Short-Term Debt issuances data on file, last reported at -$110247.0 in Q1 2020.
- Quarterly Short-Term Debt issuances fell 28.24% year-over-year to -$110247.0 in Q1 2020, while the trailing twelve-month figure through Sep 2020 was -$333264.0 (changed N/A YoY) and the FY2019 annual result came in at -$285170.0, down 3454.94% from the prior year.
- Short-Term Debt issuances improved to -$110247.0 in Q1 2020 per RLMD's latest filing, from -$223017.0 in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at -$85969.0 in Q1 2019 and bottomed at -$223017.0 in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -33,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -110,247.00 |
| Mar 31, 2020 | -110,247.00 |
| Sep 30, 2019 | -223,017.00 |
| Sep 30, 2019 | -223,017.00 |
| Jun 30, 2019 | -114,738.00 |
| Jun 30, 2019 | -114,738.00 |
| Mar 31, 2019 | -85,969.00 |
| Mar 31, 2019 | -85,969.00 |